Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 14, 1996, Pages 9-13

  Small, Gary W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GENETIC RISK; HUMAN; LIPOPROTEIN METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; FAMILY; GENETIC TECHNIQUES; GENOTYPE; HUMANS; PARIETAL LOBE; RISK ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030466582     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. St. George-Hyslop PH, Myers RH, Haines JL, et al. Familial Alzheimer's disease: progress and problems. Neurobiol Aging 1989;10:417-425
2. Breitner JC, Murphy EA, Silverman JM, et al. Age-dependent expression of familial risk in Alzheimer's disease. Am J Epidemiol 1988;128:536-548
3. Farrer LA, O'Sullivan DM, Cupples LA, et al. Assessment of genetic risk for Alzheimer's disease among first-degree relatives. Ann Neurol 1989; 25:485-493
4. Small GW, Leuchter A, Mandelkern MA, et al. Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type. Arch Neurol 1993;50:209-219
5. Nee LE, Polinsky RJ, Eldridge R, et al. A family with histologically confirmed Alzheimer's disease. Arch Neurol 1983;40:203-208
6. St. George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987;235:885-890
7. St. George-Hyslop PH, Haines JL, Farrer LA, et al. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature 1990;347:194-197
8. Pericak-Vance MA, Yamaoka LH, Haynes CS, et al. Genetic linkage studies in Alzheimer's disease families. Exp Neurol 1988;102:271-279
9. Schellenberg GD, Bird TD, Wijsman EM, et al. Absence of linkage of chromosome 21q21 markers to familial Alzheimer's disease. Science 1988; 241:1507-1510
10. Goldgaber D, Lerman MI, McBride OW, et al. Characterization and chromosomal localization of cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235:877-880
11. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-977
12. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995:376:775-778
13. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754-760
14. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706
15. Pericak-Vance MA, Bebout JL, Gaskell PC Jr, et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991;48:1034-1050
16. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977-1981
17. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472
18. Okuizumi K, Onodera O, Tanaka H, et al. ApoE-ε4 and early-onset Alzheimer's. Nature Genetics 1994;7:10-11
19. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923
20. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for the late onset Alzheimer disease. Nature Genetics 1994;7:180-184
21. Roses AD. Alzheimer's disease as a model of molecular gerontology. Journal of NIH Research 1995;7:51-57
22. Schneider LS, Tariot PN. Emerging drugs for Alzheimer's disease: mechanisms of action and prospects for cognitive enhancing medications. Med Clin North Am 1994;78:911-934
23. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:9649-9653
24. Andersen JK, Jurma OP. Use of genetically engineered mice as models for understanding human neurodegenerative disease. J Am Geriatr Soc 1996; 44:717-722
25. Greenberg BD, Savage MJ, Howland DS, et al. APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 1996;17:153-171
26. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944
27. Small GW, La Rue A, Komo S, et al. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry 1995; 152:1757-1764
28. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci. In press
29. Mazziotta JC, Phelps ME. Positron emission tomography studies of the brain. In: Phelps ME, Mazziotta JC, Schelbert HR, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986:493-579
30. Mazziotta JC, Frackowiak RSJ, Phelps ME. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med 1992; 22:233-246
31. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879-887
32. Kippenhan SJ, Barker WW, Pascal S, et al. Evaluation of a neural-network classifier for PET scans of normal and Alzheimer's disease subjects. J Nucl Med 1992;33:1459-1467
33. Powers WJ, Perlmutter JS, VideenTO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992;42:765-770
34. Herholz K, Adams R, Kessler J, et al. Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1990;1: 156-164
35. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-947
36. Soininen H, Partanen K, Pitkänen A, et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele. Neurology 1995;45:391-392
37. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996:334:752-758
38. Small OW, Mazziotta JC, Baxter LR, et al. Neuroimaging, neuropsychological, and genetic assessments for early detection of Alzheimer disease. In: Fitten LJ, ed. Facts and Research in Gerontology: Alzheimer Disease. New York, NY: Springer-Verlag. In press
39. Sunderland T, Tariot P, Murphy DL. Scopolamine challenges in Alzheimer's disease. Psychopharmacology 1985;87:247-249
40. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-1359
41. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347: 1091-1095